OncoCyte's Total Assets for the quarter that ended in Dec. 2023 was $74.89 Mil.
During the past 12 months, OncoCyte's average Total Assets Growth Rate was -17.80% per year.
During the past 3 years, the average Total Assets Growth Rate was 11.20% per year.
During the past 5 years, the average Total Assets Growth Rate was 111.20% per year.
During the past 10 years, the average Total Assets Growth Rate was 58.50% per year.
During the past 11 years, OncoCyte's highest 3-Year average Total Assets Growth Rate was 391.90%. The lowest was -21.60%. And the median was 38.60%.
Total Assets is connected with ROA %. OncoCyte's annualizedROA % for the quarter that ended in Dec. 2023 was -81.76%. Total Assets is also linked to Revenue through Asset Turnover. OncoCyte's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.
OncoCyte Total Assets Historical Data
The historical data trend for OncoCyte's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
OncoCyte's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
OncoCyte's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
OncoCyte Total Assets Related Terms
Thank you for viewing the detailed overview of OncoCyte's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OCX has been successfully added to your 